BridgeMD
Tests treatment safety and results for T2DM
Official title A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes Mellitus
ClinicalTrials.gov ID: NCT07599410
What this study is testing
What is HRS9531 Tablet?
HRS9531 Tablet is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for t2dm.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The aim of the trial is to investigate the efficacy and safety of HRS9531 tablets versus placebo in participants with type 2 diabetes mellitus who failed to achieve adequate glycemic control on lifestyle intervention alone or on a stable dose of metformin. This study will last 20 weeks.
- Phase 2: a mid-size study of how well it works
- Time commitment: about 20 weeks
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Male or female, aged 18 to 70 years on the day of signing the informed consent form;
- Have a documented history of type 2 diabetes mellitus for at least 6 months at screening, diagnosed according to the criteria in Guidelines for the...
- HbA1c between 7.5% and 10.5% at screening;
- Have received lifestyle intervention alone for at least 8 weeks, or stable metformin monotherapy for at least 8 weeks prior to screening. Stable...
- Fasting plasma glucose ≤ 15 mmol/L;
You likely can't join if
- Participants with relevant abnormal test results at screening.
- Participants with clinically significant abnormal findings on electrocardiogram (ECG) that, in the investigator's opinion, may compromise subject...
- Participants with poorly controlled blood pressure.
- Participants diagnosed with or suspected of having type 1 diabetes, specific types of diabetes, or secondary diabetes.
- Participants who experienced acute diabetic complications within 6 months prior to screening.
- Participants who experienced severe hypoglycemic events or recurrent hypoglycemic events within 6 months prior to screening.
See the full eligibility criteria
- Male or female, aged 18 to 70 years on the day of signing the informed consent form;
- Have a documented history of type 2 diabetes mellitus for at least 6 months at screening, diagnosed according to the criteria in Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2024 Edition);
- HbA1c between 7.5% and 10.5% at screening;
- Have received lifestyle intervention alone for at least 8 weeks, or stable metformin monotherapy for at least 8 weeks prior to screening. Stable treatment is defined as no change in daily drug dosage, with no planned...
- Fasting plasma glucose ≤ 15 mmol/L;
- Body mass index (BMI) between 20.0 kg/m² and 40.0 kg/m² at screening;
- Voluntarily sign the informed consent form before the trial, fully understand the trial content, procedures and potential adverse reactions, and be able and willing to comply with protocol requirements to complete the...
- Have no fertility plans from the signing of the informed consent form until 2 months after the last dose, and agree to use highly effective contraceptive measures as specified in the protocol.methods.
- Participants with relevant abnormal test results at screening.
- Participants with clinically significant abnormal findings on electrocardiogram (ECG) that, in the investigator's opinion, may compromise subject safety.
- Participants with poorly controlled blood pressure.
- Participants diagnosed with or suspected of having type 1 diabetes, specific types of diabetes, or secondary diabetes.
- Participants who experienced acute diabetic complications within 6 months prior to screening.
- Participants who experienced severe hypoglycemic events or recurrent hypoglycemic events within 6 months prior to screening.
- Participants with severe chronic diabetic complications at screening, or non-proliferative diabetic retinopathy requiring treatment during the trial.
- Participants with a past or known history or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
- Participants with a past or known history of acute or chronic pancreatitis, pancreatic injury, acute cholecystitis, or symptomatic/treatment requiring gallbladder disease.
- Participants with a past history of significant gastrointestinal diseases (such as severe diabetic gastroparesis, gastric outlet obstruction, inflammatory bowel disease, active ulcer, etc.), or who have undergone...
- Participants with a history of severe cardiovascular or cerebrovascular diseases within 6 months prior to screening.
- Participants with known or suspected depression, bipolar disorder, suicidal ideation, schizophrenia, or other severe psychiatric disorders; or participants who are mentally incompetent, have language barriers, are...
- Participants with a history of malignant tumor within 5 years prior to screening, except for cured localized cancers such as localized basal cell carcinoma of the skin, cervical carcinoma in situ, and prostate carcinoma...
- Female participants who are pregnant, breastfeeding, or planning to become pregnant during the trial.
- Any other conditions that, in the investigator's judgment, render the subject unsuitable for participation in this clinical trial.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
- Jinan, Shandong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 20 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China; Jinan, Shandong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.